Rapport Therapeutics, Inc. RAPP
Set alert
At close · Oct 30
After hours · Oct 30, 7:59 PM ET
- YTD
- -17.44%
- 1 year
- -6.81%
- Open
- 23.94
- Prev close
- 24.21
- Mkt cap
- 1.20B
- Vol
- 926.56K
- Avg vol
- 686.27K
- EPS
- -3.03
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 23.86
- High
- 25.43
- Forward P/E
- -4.92
- Beta
- 1.22
- Short ratio
- 6.70
- Inst. own
- 109.65%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 37.16
- 200-d avg
- 35.66
- 1y target
- 68.29
5D chart
Signals (131)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 29, 3:40 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:15 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:10 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:45 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:35 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:50 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:45 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:40 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:35 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:30 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:15 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:40 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:35 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 11:35 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 11:25 AM | 3 days ago |
| RSI: Overbought | Oct 29, 11:25 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:15 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 11:10 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:05 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:15 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:00 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:45 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:40 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 3 days ago |
| RSI: Oversold | Oct 28, 3:00 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:00 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:00 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:40 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:25 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:20 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 11:00 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:50 AM | 4 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:25 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:00 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 2:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 2:45 PM | 4 days ago |
| RSI: Overbought | Oct 27, 2:35 PM | 4 days ago |
| RSI: Overbought | Oct 27, 2:20 PM | 4 days ago |
| RSI: Overbought | Oct 27, 1:55 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 4 days ago |
| RSI: Overbought | Oct 27, 1:20 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:15 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 1:05 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 12:30 PM | 5 days ago |
| RSI: Overbought | Oct 27, 12:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 11:45 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:40 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:30 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:35 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:20 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:10 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:45 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:40 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:35 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:35 PM | 5 days ago |
| RSI: Oversold | Oct 26, 3:20 PM | 5 days ago |
| RSI: Oversold | Oct 26, 2:45 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 2:35 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:05 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 2:05 PM | 5 days ago |
| RSI: Oversold | Oct 26, 1:40 PM | 5 days ago |
| SMA: Bearish | Oct 26, 11:40 AM | 6 days ago |
| MACD: Sell Signal | Oct 26, 11:40 AM | 6 days ago |
| MACD: Buy Signal | Oct 26, 11:35 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:10 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:40 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:35 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 6 days ago |
| MACD: Sell Signal | Oct 26, 10:30 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:25 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:15 AM | 6 days ago |
| MACD: Buy Signal | Oct 26, 10:15 AM | 6 days ago |
| MACD: Sell Signal | Oct 26, 10:05 AM | 6 days ago |
| SMA: Bearish | Oct 26, 9:55 AM | 6 days ago |
| SMA: Bullish | Oct 26, 9:30 AM | 6 days ago |
| SMA: Bullish | Oct 26, 9:30 AM | 6 days ago |
| RSI: Overbought | Oct 26, 9:30 AM | 6 days ago |
| SMA: Bearish | Oct 23, 3:55 PM | 1 week ago |
| SMA: Bearish | Oct 23, 3:55 PM | 1 week ago |
| SMA: Bullish | Oct 23, 3:35 PM | 1 week ago |
| SMA: Bullish | Oct 23, 3:35 PM | 1 week ago |
| MACD: Buy Signal | Oct 23, 3:30 PM | 1 week ago |
| MACD: Sell Signal | Oct 23, 3:10 PM | 1 week ago |
| RSI: Oversold | Oct 23, 3:10 PM | 1 week ago |
| SMA: Bearish | Oct 23, 3:00 PM | 1 week ago |
| MACD: Buy Signal | Oct 23, 2:40 PM | 1 week ago |
| SMA: Bearish | Oct 23, 2:35 PM | 1 week ago |
| SMA: Bullish | Oct 23, 2:30 PM | 1 week ago |
| MACD: Sell Signal | Oct 23, 1:00 PM | 1 week ago |
| SMA: Bearish | Oct 23, 12:50 PM | 1 week ago |
| SMA: Bearish | Oct 23, 12:50 PM | 1 week ago |
| SMA: Bullish | Oct 23, 12:30 PM | 1 week ago |
| SMA: Bearish | Oct 23, 12:20 PM | 1 week ago |
| SMA: Bearish | Oct 23, 12:20 PM | 1 week ago |
| SMA: Bullish | Oct 23, 12:15 PM | 1 week ago |
| SMA: Bullish | Oct 23, 12:15 PM | 1 week ago |
| SMA: Bearish | Oct 23, 12:05 PM | 1 week ago |
| SMA: Bullish | Oct 23, 11:50 AM | 1 week ago |
| SMA: Bearish | Oct 23, 11:40 AM | 1 week ago |
| SMA: Bullish | Oct 23, 11:25 AM | 1 week ago |
| SMA: Bearish | Oct 23, 11:20 AM | 1 week ago |
| SMA: Bullish | Oct 23, 11:10 AM | 1 week ago |
| SMA: Bearish | Oct 23, 11:00 AM | 1 week ago |
| SMA: Bullish | Oct 23, 10:50 AM | 1 week ago |
News
3 days ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular session. The company's market cap stands at $85.0 million. As per the press release, Q3 earnings came out…
4 days ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Axogen (NASDAQ:AXGN) stock rose 17.7% to $44.1 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q3 earnings report…
4 days ago benzinga.com
Enphase Energy Posts Downbeat Q3 Results, Joins NXP Semiconductors, Seagate And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures mixed as Enphase plunges 17% after earnings and weak guidance; Rapport, Intapp, Logitech and others also fall premarket.
-
4 days ago benzinga.com
Rapport Therapeutics Prices Separate Offerings Of ~$175M Of Stock At $21.00/Share, Warrants To Purchase Up To ~$25M Of Stock At $20.999 Per Pre-Funded Warrant, And $150M Of 2.25% Convertible Senior Notes Due 2032
Concurrently with the underwritten offerings, Rapport entered into a share purchase agreement with a certain investor (the "Investor"), in a separately negotiated transaction (the "concurrent private
4 days ago globenewswire.com
Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement
BOSTON and SAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and…
4 days ago benzinga.com
Why Ultra Clean Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Ultra Clean shares surged 14.6% after beating earnings and sales estimates; Ultralife soared 143.8% on a $320M acquisition deal.
4 days ago benzinga.com
Rapport Therapeutics (RAPP) Shares Sink 20% After Hours
Rapport Therapeutics stock falls after hours as investors assess proposed stock and convertible notes offerings.
-
4 days ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Neumora Therapeutics (NASDAQ:NMRA) shares rose 11.9% to $0.41 during Tuesday's after-market session. The market value of their outstanding shares is at $73.8 million. Pulmonx (NASDAQ:LUNG)…
-
4 days ago benzinga.com
Rapp Therapeutics Files For Offering Of Common Stock; Size Not Disclosed
Common StockWe are offering $ of shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus.Our common stock is listed on The Nasdaq Global Market under the…
-
4 days ago benzinga.com
Rapport Therapeutics Commences Separate Underwritten Public Offerings Of $200M Of Shares And $150M Aggregate Principal Amount Of Convertible Senior Notes Due 2032
Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for…
4 days ago globenewswire.com
Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement
BOSTON and SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and…
6 days ago defenseworld.net
Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) CEO Sells $64,443.60 in Stock
Rapport Therapeutics, Inc. (NASDAQ: RAPP - Get Free Report) CEO Abraham Ceesay sold 2,210 shares of Rapport Therapeutics stock in a transaction dated Wednesday, October 21st. The shares were sold at…
6 days ago marketbeat.com
Rapport Therapeutics' RAP-219 Hits Phase II Goals in Bipolar Mania Trial
Rapport Therapeutics NASDAQ: RAPP reported positive top-line results from a Phase II proof-of-concept trial of RAP-219 in adults with acute bipolar mania, meeting both its primary and secondary…
-
1 week ago benzinga.com
Jones Trading Maintains Buy on Rapport Therapeutics, Raises Price Target to $82
Jones Trading analyst Justin Walsh maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $50 to $82.
-
1 week ago benzinga.com
Wells Fargo Maintains Overweight on Rapport Therapeutics, Lowers Price Target to $50
Wells Fargo analyst Benjamin Burnett maintains Rapport Therapeutics (NASDAQ:RAPP) with a Overweight and lowers the price target from $51 to $50.
-
1 week ago benzinga.com
Guggenheim Maintains Buy on Rapport Therapeutics, Raises Price Target to $70
Guggenheim analyst Delma Caiati maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $65 to $70.
1 week ago seekingalpha.com
Rapport Therapeutics, Inc. (RAPP) Discusses Phase II Bipolar Mania Trial Results and Business Update Transcript
Rapport Therapeutics, Inc. (RAPP) Discusses Phase II Bipolar Mania Trial Results and Business Update Transcript
-
1 week ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Rapport Therapeutics, Maintains $66 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains $66 price target.
1 week ago benzinga.com
Why Is Rapport Therapeutics Stock Trading Higher Today?
Rapport Therapeutics Inc. (NASDAQ:RAPP) stock is trading higher on Tuesday with a premarket session volume of 1.439 million versus the average volume of 351.078 thousand, according to Benzinga Pro…
1 week ago benzinga.com
Why Is Rapport Therapeutics Stock Trading Higher Today?
Rapport Therapeutics posts positive Phase 2 trial results for RAP-219 in acute bipolar mania, setting up Phase 3 studies in 2027.
1 week ago barrons.com
Inside the $1 Billion Blockbuster Opportunity That Has Rapport Therapeutics Stock Surging
Positive trial data for Rapport's lead pipeline candidate, RAP-219, a treatment for bipolar mania, points to a potential $1 billion peak sales opportunity, Jefferies says.
1 week ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers SCWorx (NASDAQ:WORX) stock rose 47.8% to $3.96 during Tuesday's pre-market session. Integra Lifesciences (NASDAQ:IART) shares increased by 31.97% to $17.75. The market value of their…
-
1 week ago benzinga.com
BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $89
BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $75 to $89.
-
1 week ago benzinga.com
Rapport Therapeutics Announces That Topline Results From Its Phase 2 Trial Of RAP-219 In Adults With Acute Bipolar Mania Met Primary Endpoint
The trial met the primary and secondary endpoints with statistically significant placebo-adjusted improvements at Week 3 in the YMRS total score (3.1 points; p=0.045) and CGI-BP Severity of Mania…
1 week ago globenewswire.com
Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania
The trial met the primary and secondary endpoints with statistically significant placebo-adjusted improvements at Week 3 in the YMRS total score (3.1 points; p=0.045) and CGI-BP Severity of Mania…
-
1 week ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Disc Medicine (NASDAQ:IRON) stock moved upwards by 50.4% to $85.51 during Monday's pre-market session. The company's market cap stands at $2.1 billion. DataMEDS AI (NASDAQ:MEDS) shares moved…
-
2 weeks ago benzinga.com
UBS Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $71
UBS analyst Joon Lee initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and announces Price Target of $71.
-
2 weeks ago benzinga.com
Wolfe Research Initiates Coverage On Rapport Therapeutics with Outperform Rating, Announces Price Target of $50
Wolfe Research initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Outperform rating and announces Price Target of $50.
-
3 weeks ago benzinga.com
Guggenheim Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $65
Guggenheim analyst Delma Caiati initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and announces Price Target of $65.
1 month ago seekingalpha.com
Rapport: Bipolar Mania Readout May Distort True Value Of Anti-Seizure Med - Rating Upgrade
Rapport Therapeutics stock fell ~18% as investors digested updates on lead candidate RAP-219 and anticipated Phase 2 bipolar mania data. RAP-219 shows strong efficacy in focal onset seizures, with up…
1 month ago seekingalpha.com
Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania Transcript
Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania Transcript
1 month ago zacks.com
4 Biotech Stocks With Key Clinical Readouts Expected This Fall
KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.
1 month ago benzinga.com
Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
1 month ago benzinga.com
Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday
Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with several rating upgrades and downgrades.
-
1 month ago benzinga.com
BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $75
BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $65 to $75.
1 month ago defenseworld.net
Legal & General Group Plc Acquires Shares of 22,555 Rapport Therapeutics, Inc. $RAPP
Legal and General Group Plc acquired a new stake in shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP) during the undefined quarter, according to the company in its most recent filing with the…
2 months ago globenewswire.com
Rapport Therapeutics to Participate in Upcoming Investor Conferences
BOSTON and SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and…
2 months ago defenseworld.net
Deutsche Bank AG Takes $1.34 Million Position in Rapport Therapeutics, Inc. $RAPP
Deutsche Bank AG acquired a new position in shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP) during the undefined quarter, according to the company in its most recent 13F filing with the…
2 months ago defenseworld.net
Algert Global LLC Purchases Shares of 223,822 Rapport Therapeutics, Inc. $RAPP
Algert Global LLC purchased a new position in shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP) during the undefined quarter, according to the company in its most recent disclosure with the SEC.…
2 months ago defenseworld.net
Rapport Therapeutics (NASDAQ:RAPP) Sets New 12-Month High – Time to Buy?
Rapport Therapeutics, Inc. (NASDAQ: RAPP - Get Free Report) shares reached a new 52-week high during mid-day trading on Tuesday. The company traded as high as $50.34 and last traded at $49.33, with a…
2 months ago globenewswire.com
Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program
BOSTON and SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and…
2 months ago seekingalpha.com
Rapport Therapeutics: A 22-Day Half-Life Creates A Differentiated Epilepsy Franchise
Rapport Therapeutics is differentiated by RAP-219's neuroanatomically selective pharmacology and a 22-day half-life, supporting a bullish outlook. RAPP is fully funded through pivotal Phase 3 trials,…
-
2 months ago benzinga.com
BTIG Reiterates Buy on Rapport Therapeutics, Maintains $65 Price Target
BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains $65 price target.
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Rapport Therapeutics, Raises Price Target to $66
HC Wainwright & Co. analyst Douglas Tsao maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $40 to $66.
-
2 months ago benzinga.com
BTIG Reiterates Buy on Rapport Therapeutics, Maintains $65 Price Target
BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains $65 price target.
-
2 months ago benzinga.com
Rapport Therapeutics Q2 EPS $(1.19) Misses $(0.96) Estimate
Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(1.19) per share which missed the analyst consensus estimate of $(0.96) by 23.96 percent. This is a 58.67 percent decrease over losses…
2 months ago globenewswire.com
Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update
RAP-219 Phase 3 program in focal onset seizures initiated, with FOCUS 1 and FOCUS 2 trials enrolling patients RAP-219 Phase 2 trial in bipolar mania on track for topline results in October 2026…
-
3 months ago benzinga.com
BTIG Reiterates Buy on Rapport Therapeutics, Maintains $65 Price Target
BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains $65 price target.
-
4 months ago benzinga.com
Leerink Partners Initiates Coverage On Rapport Therapeutics with Outperform Rating, Announces Price Target of $52
Leerink Partners analyst Marc Goodman initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Outperform rating and announces Price Target of $52.
-
5 months ago benzinga.com
BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $65
BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $53 to $65.